Tag: acute care syndromic testing market trends

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

The acute care syndromic testing market has experienced rapid expansion recently, driven by increasing healthcare needs and advancements in diagnostic technologies. As infectious diseases continue to pose significant challenges worldwide, this market is set to grow substantially, supported by innovations and growing demand across various healthcare settings. Below is a detailed insight into the market size, growth drivers, segmentation, trends, key players, and geographical outlook.

Market Size and Projected Growth of the Acute Care Syndromic Testing Market

The acute care syndromic testing market has seen remarkable growth in recent years. Market value is projected to rise from $4.59 billion in 2025 to $5.17 billion in 2026, representing a compound annual growth rate (CAGR) of 12.8%. This upswing during the historical period is largely attributed to increased demand for rapid infection diagnostics, the expansion of hospital ICUs, initiatives aimed at outbreak preparedness, wider adoption of molecular diagnostics, and optimization of critical care workflows.

Looking ahead, the market is expected to continue its upward trajectory, reaching $8.3 billion by 2030 with a CAGR of 12.5%. Factors contributing to this growth include the introduction of AI-powered syndromic panels, broader emergency testing capabilities, antimicrobial stewardship programs, point-of-care molecular testing systems, and heightened focus on pandemic preparedness. Key emerging trends anticipated to shape the industry include rapid multiplex pathogen detection, molecular testing in emergency departments, multi-disease panels from a single sample, faster clinical decision support tools, and reduced diagnostic turnaround times.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

Main Factors Supporting Growth in the Acute Care Syndromic Testing Market

One of the primary drivers behind the acute care syndromic testing market expansion is the rising prevalence of infectious diseases. These illnesses, caused by harmful microorganisms like bacteria, viruses, fungi, and parasites, can spread through human contact, animals, or environmental exposure. A range of factors such as population growth, increased urbanization, global travel, antimicrobial resistance, and climate change contribute to this surge, creating a greater need for effective diagnosis and treatment.

Acute care syndromic testing plays a critical role in managing infectious diseases by rapidly identifying pathogens and co-infections using multiplex molecular diagnostics. This enables healthcare providers to make targeted treatment decisions quickly. For instance, in February 2024, the UK’s Health Security Agency reported that the influenza positivity rate jumped to 16.6% in week 4, rising from 14.0% the previous week. Additionally, influenza-like illness consultations increased, as did hospitalizations due to influenza, highlighting the ongoing demand for swift and accurate diagnostic solutions.

Key Segments Expanding within the Acute Care Syndromic Testing Market

This market is divided into several important categories to better understand its composition and growth areas:

1) Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, and Other Disease Types

2) Sample Type: Blood, Urine, Biofluids, Stool, Swabs, and Other Sample Types

3) Target Pathogen: Bacteria, Viruses, Fungi, Parasites

4) End User: Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutions, and Other Users

Further breakdowns include specific respiratory diseases such as Influenza, Respiratory Syncytial Virus (RSV), COVID-19, and Tuberculosis; gastrointestinal diseases like Clostridium Difficile Infection and Norovirus; genitourinary infections including UTIs and STIs; tropical diseases such as Malaria and Dengue; and other emerging infections like Meningitis and Sepsis.

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Acute Care Syndromic Testing Market Geographic Analysis: Where Is Demand Growing The Fastest?

Technological Developments Shaping the Acute Care Syndromic Testing Market

Leading players in the acute care syndromic testing sector are focusing on advancements like multiplex real-time polymerase chain reaction (PCR) technology. This technique enhances diagnostic precision by detecting multiple pathogens in a single test, speeding up results, streamlining laboratory processes, and ultimately improving patient care through timely treatment decisions.

For example, in April 2023, QIAGEN N.V., a biotech firm based in the Netherlands, introduced its QIAstat-Dx syndromic testing system in Japan. This product features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from one sample using multiplex real-time PCR. It provides quick results with less manual effort compared to individual PCR tests and is available in more than 100 countries, increasing global access to syndromic testing.

Prominent Companies Leading the Acute Care Syndromic Testing Market

The market features several major corporations driving innovation and competition, including Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., and Applied BioCode Inc.

Geographical Landscape and Market Expansion

In 2025, North America held the largest share of the acute care syndromic testing market. However, the report covers a broad geographic scope including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. These regions reflect varying growth potentials and adoption rates, with Asia-Pacific and other developing regions expected to show significant market expansion in the coming years.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Acute Care Syndromic Testing Market Through 2030?

The acute care syndromic testing market has demonstrated rapid expansion in recent years. This market is projected to grow from $4.59 billion in 2025 to $5.17 billion in 2026, at a compound annual growth rate (CAGR) of 12.8%. The historical growth can be attributed to several factors, including the demand for emergency infection diagnosis, the expansion of hospital ICUs, initiatives for outbreak preparedness, the adoption of molecular diagnostics, and the optimization of critical care workflows.

The acute care syndromic testing market size is predicted to experience swift growth over the upcoming period. It is expected to expand to $8.3 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.5%. This projected increase is driven by elements such as AI-enabled syndromic panels, the broadening of emergency testing, antimicrobial stewardship initiatives, point-of-care molecular systems, and a sharpened focus on pandemic preparedness. Significant trends expected during this forecast include rapid multiplex pathogen detection, molecular testing within emergency departments, multi-disease panels utilizing single samples, enhanced clinical decision support, and a reduction in diagnostic turnaround time.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

Which Major Factors Are Contributing To The Development Of The Acute Care Syndromic Testing Market?

The rising occurrence of infectious diseases is anticipated to stimulate the acute care syndromic testing market moving forward. Infectious diseases are illnesses stemming from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, which possess the ability to spread between individuals, animals, or through the environment. The increasing prevalence of infectious diseases is fueled by factors including population growth, urbanization, international travel, antimicrobial resistance, and climate change, thereby amplifying the necessity for effective prevention and treatment. Acute care syndromic testing is employed in infectious diseases to rapidly identify pathogens and co-infections through multiplex molecular diagnostics, facilitating precise treatment decisions. For instance, in February 2024, according to the Health Security Agency, a UK-based government agency, week 4 of 2024 saw the influenza positivity rate climb to 16.6%, an increase from 14.0% the previous week. Consultations for influenza-like illness (ILI) also rose, reaching 9.8 per 100,000 people, compared to 7.5 per 100,000 in the prior week. Additionally, influenza hospitalizations ascended to 7.63 per 100,000, up from 5.12 per 100,000 the week before. Thus, the escalating incidence of infectious diseases is a key driver for the acute care syndromic testing market.

What Key Segment Areas Are Included In The Acute Care Syndromic Testing Market Assessment?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Which Trends Are Expected To Shape The Acute Care Syndromic Testing Market?

Major companies within the acute care syndromic testing market are concentrating on technological progress, particularly multiplex real-time polymerase chain reaction (PCR) technology, to improve diagnostic accuracy, facilitate rapid pathogen detection, streamline laboratory workflows, decrease turnaround time, and better patient outcomes via precise and prompt treatment. Multiplex real-time PCR technology represents a sophisticated molecular diagnostic approach that simultaneously identifies and quantifies several pathogens or genetic targets in a single PCR reaction, boosting the efficiency and accuracy of disease diagnosis. For example, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research company, launched the QIAstat-Dx syndromic testing solution in Japan, which includes a SARS-CoV-2 respiratory panel that can detect over 20 pathogens from a single sample. Utilizing multiplex real-time PCR technology, this system delivers quick results with minimal labor in contrast to individual PCR assays. The system is available in over 100 countries, thereby increasing the worldwide accessibility of syndromic testing.

Who Are The Major Companies Operating In The Acute Care Syndromic Testing Market?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Access The Complete Acute Care Syndromic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Which Region Contributes The Most To The Acute Care Syndromic Testing Market?

North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Acute Care Syndromic Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company

Tele Intensive Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report

Severe Acute Respiratory Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Tele Intensive Care Unit Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Acute Care Syndromic Testing Market Between 2026 And 2030?

The acute care syndromic testing market has experienced significant expansion in recent years. This market is projected to grow from $4.59 billion in 2025 to $5.17 billion in 2026, showing a compound annual growth rate (CAGR) of 12.8%. The historical increase can be attributed to several key factors, including the demand for emergency infection diagnosis, the expansion of hospital ICUs, various outbreak preparedness initiatives, the adoption of molecular diagnostics, and the optimization of critical care workflows.

The acute care syndromic testing market is projected for significant expansion in the coming years. It is forecast to reach $8.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. Key drivers contributing to this growth during the projection period include AI-enabled syndromic panels, expanded emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, and an increased focus on pandemic preparedness. Significant trends anticipated over the forecast timeframe encompass rapid multiplex pathogen detection, molecular testing in emergency departments, single-sample multi-disease panels, enhanced clinical decision support speed, and a reduction in diagnostic turnaround time.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What Primary Drivers Are Shaping The Acute Care Syndromic Testing Market?

The increasing occurrence of infectious diseases is anticipated to drive the acute care syndromic testing market in the future. These diseases are illnesses resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which have the potential to spread among individuals, animals, or through the environment. The rise in infectious disease cases is fueled by elements such as an expanding population, increasing urbanization, international travel, resistance to antimicrobials, and changes in climate, all of which heighten the demand for effective methods of prevention and treatment. In the context of infectious diseases, acute care syndromic testing employs multiplex molecular diagnostics for swift identification of pathogens and concurrent infections, thereby facilitating precise treatment choices. For example, data from February 2024, provided by the Health Security Agency, a UK-based government body, showed that during week 4 of 2024, the influenza positivity rate rose to 16.6% from 14.0% in the prior week. Consultations for influenza-like illness (ILI) also saw an increase, reaching 9.8 per 100,000 people, an escalation from 7.5 per 100,000 in the week before. Furthermore, influenza hospitalizations ascended to 7.63 per 100,000, an increase from 5.12 per 100,000 in the preceding week. Consequently, the increasing prevalence of infectious diseases is propelling the acute care syndromic testing market.

How Is The Acute Care Syndromic Testing Market Organized By Segment Classification?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

What Trends Are Affecting The Growth Of The Acute Care Syndromic Testing Market?

Leading companies within the acute care syndromic testing market are concentrating on technological breakthroughs, such as multiplex real-time polymerase chain reaction (PCR) technology, to elevate diagnostic precision, enable swift pathogen identification, optimize laboratory workflows, reduce turnaround times, and ultimately improve patient outcomes through accurate and timely treatment strategies. This multiplex real-time PCR technology is an advanced molecular diagnostic technique that concurrently identifies and quantifies multiple pathogens or genetic targets in a single PCR reaction, thereby enhancing both efficiency and accuracy in disease diagnosis. For example, in April 2023, QIAGEN N.V., a biotechnology research company headquartered in the Netherlands, released its QIAstat-Dx syndromic testing solution in Japan. This solution incorporates a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. By employing multiplex real-time PCR technology, it yields rapid results with significantly less labor compared to individual PCR assays. The system is presently offered in more than 100 countries, thereby boosting the global accessibility of syndromic testing.

Who Are The Industry Participants Involved In The Acute Care Syndromic Testing Market?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Get The Full Acute Care Syndromic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Which Region Accounts For The Largest Portion Of The Acute Care Syndromic Testing Market?

North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acute Care Syndromic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company

Tele Intensive Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report

Severe Acute Respiratory Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Tele Intensive Care Unit Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Acute Care Syndromic Testing Market From 2026 To 2030?

The market size for acute care syndromic testing has seen substantial growth in recent years. This sector is expected to expand from $4.59 billion in 2025 to $5.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.8%. Historically, this market expansion can be linked to the demand for emergency infection diagnosis, the growth of hospital intensive care units, initiatives for outbreak preparedness, the adoption of molecular diagnostics, and optimization of critical care workflows.

The acute care syndromic testing market is projected for substantial expansion over the upcoming years. It will grow to $8.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. This anticipated growth during the forecast period is largely due to factors such as AI-enabled syndromic panels, the broadening of emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, and an increased focus on pandemic preparedness. Key trends anticipated during this period encompass rapid multiplex pathogen detection, molecular testing within emergency departments, multi-disease panels utilizing single samples, expedited clinical decision support, and a reduction in diagnostic turnaround time.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What Major Drivers Are Influencing Demand In The Acute Care Syndromic Testing Market?

The acute care syndromic testing market is projected to be propelled by the increasing occurrence of infectious diseases. These diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that have the ability to spread from person to person, animals, or the environment. The rising incidence of infectious diseases is fueled by elements such as population growth, urbanization, global travel, antimicrobial resistance, and climate change, thereby escalating the demand for effective prevention and treatment. Acute care syndromic testing is employed in infectious diseases for the rapid identification of pathogens and co-infections through multiplex molecular diagnostics, which facilitates targeted treatment decisions. For instance, in February 2024, according to the Health Security Agency, a UK-based government agency, during week 4 of 2024, the influenza positivity rate saw an increase to 16.6%, rising from 14.0% in the preceding week. Influenza-like illness (ILI) consultations also experienced a rise, reaching 9.8 per 100,000 people, up from 7.5 per 100,000 in the prior week. Additionally, influenza hospitalizations ascended to 7.63 per 100,000, an increase from 5.12 per 100,000 the week before. Thus, the escalating incidence of infectious diseases is a key driver for the acute care syndromic testing market.

Which Segments Are Included In The Analysis Of The Acute Care Syndromic Testing Market?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Which Trends Are Impacting The Growth Of The Acute Care Syndromic Testing Market?

Major companies engaged in the acute care syndromic testing market are concentrating on technological innovations, such as multiplex real-time polymerase chain reaction (PCR) technology. This strategic focus aims to improve diagnostic precision, facilitate rapid pathogen identification, optimize laboratory workflows, reduce result turnaround times, and ultimately enhance patient outcomes through accurate and prompt treatment. Multiplex real-time PCR technology represents an advanced molecular diagnostic method capable of simultaneously detecting and quantifying multiple pathogens or genetic targets within a single PCR reaction, thereby boosting the efficiency and accuracy of disease diagnosis. For instance, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research firm, introduced its QIAstat-Dx syndromic testing solution in Japan. This solution incorporates a SARS-CoV-2 respiratory panel that can identify over 20 pathogens from a single sample. Leveraging multiplex real-time PCR technology, the system provides quick results with minimal labor compared to performing individual PCR assays. Its availability in over 100 countries globally significantly improves the accessibility of syndromic testing worldwide.

Which Key Industry Participants Are Active In The Acute Care Syndromic Testing Market?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Read the full acute care syndromic testing market report here:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Acute Care Syndromic Testing Market?

North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Care Syndromic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company

Tele Intensive Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report

Severe Acute Respiratory Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Tele Intensive Care Unit Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the artificial intelligence (ai) image upscaling chip market from 2026–2035 with trusted insights from The Business Research Company

How much is the Acute Care Syndromic Testing Market valued at in 2026, and what valuation is forecast for 2030?

The market for acute care syndromic testing has witnessed substantial expansion in recent years. This sector is anticipated to increase from $4.59 billion in 2025 to $5.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.8%. Throughout the historical period, this expansion has been propelled by elements like the necessity for emergency infection diagnosis, the enlargement of hospital ICUs, strategies for outbreak readiness, the embrace of molecular diagnostics, and the enhancement of critical care operational processes.

The acute care syndromic testing market size is projected for significant expansion in the coming years. This market is anticipated to reach $8.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. Key factors driving this growth during the forecast period include AI-enabled syndromic panels, increased emergency testing, antimicrobial stewardship initiatives, advancements in point-of-care molecular systems, and an enhanced focus on pandemic preparedness. Significant trends expected over the same period encompass rapid multiplex pathogen detection, the integration of molecular testing in emergency departments, the development of single-sample multi-disease panels, improvements in clinical decision support speed, and a reduction in diagnostic turnaround time.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What Drivers Are Influencing The Growth Of The Acute Care Syndromic Testing Market?

An increasing occurrence of infectious diseases is anticipated to drive the acute care syndromic testing market in the future. These diseases are defined as ailments resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, capable of transmission among individuals, animals, or through the environment. The rise in infectious disease cases stems from factors including population expansion, urbanization, international travel, antimicrobial resistance, and climate change, thereby intensifying the demand for effective prevention and treatment. For infectious diseases, acute care syndromic testing employs multiplex molecular diagnostics to quickly pinpoint pathogens and co-infections, facilitating precise treatment choices. For example, data from February 2024, released by the UK’s Health Security Agency, showed that in week 4 of 2024, the influenza positivity rate climbed to 16.6% from 14.0% in the preceding week. Furthermore, consultations for influenza-like illness (ILI) also saw an increase, reaching 9.8 per 100,000 people, an uplift from 7.5 per 100,000 in the week prior. Similarly, influenza hospital admissions advanced to 7.63 per 100,000, rising from 5.12 per 100,000 the week before. Consequently, the escalating occurrence of infectious diseases is a key factor propelling the acute care syndromic testing market.

How Is The Acute Care Syndromic Testing Market Organized Into Various Segments?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Which Trends Are Expected To Influence The Acute Care Syndromic Testing Market In The Upcoming Years?

Leading companies within the acute care syndromic testing market are concentrating on technological innovations, such as multiplex real-time polymerase chain reaction (PCR) technology. This focus aims to enhance diagnostic accuracy, facilitate rapid pathogen detection, streamline laboratory workflows, decrease turnaround time, and improve patient outcomes through precise and timely treatment interventions. Multiplex real-time PCR technology is an advanced molecular diagnostic method that simultaneously identifies and quantifies multiple pathogens or genetic targets in a single PCR reaction, thereby increasing efficiency and accuracy in disease diagnosis. For example, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research company, introduced the QIAstat-Dx syndromic testing solution in Japan. This solution features a SARS-CoV-2 respiratory panel designed to detect over 20 pathogens from a single sample. Utilizing multiplex real-time PCR technology, it delivers quick results with minimal labor requirements compared to individual PCR assays. This system is available in over 100 countries, consequently enhancing syndromic testing accessibility across the globe.

Who Are The Primary Competitors In The Global Acute Care Syndromic Testing Market?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Acute Care Syndromic Testing Market?

North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Acute Care Syndromic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company

Tele Intensive Care Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report

Severe Acute Respiratory Syndrome Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Tele Intensive Care Unit Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Acute Care Syndromic Testing Market?

The market for acute care syndromic testing has experienced swift expansion lately, projected to climb from a valuation of $4.08 billion in 2024 to $4.59 billion by 2025, showcasing a compound annual growth rate (CAGR) amounting to 12.3%. This upward trajectory during the past period stems from several contributing factors, including heightened consciousness regarding antimicrobial resistance, an upswing in governmental financial support directed towards infectious disease initiatives, augmented investment flowing into healthcare facilities, a greater emphasis placed on syndromic testing methodologies, the broader adoption of telemedicine, and an overall increase in the incidence of infectious diseases.

Anticipated within the upcoming years is substantial expansion for the acute care syndromic testing sector; by the year 2029, its valuation is projected to reach $7.39 billion, achieving a compound annual growth rate (CAGR) of 12.7%, with this upward trajectory being fueled by several key factors, including the increasing incidence of infectious ailments, a heightened need for expedited diagnostic methods, the broadening scope of medical services offered, increased deployment of syndromic panels capable of simultaneous testing, and the aging demographic bulge. Furthermore, the forthcoming period is set to be characterized by significant shifts such as a move towards diagnostics administered at the point of care, the incorporation of web-based infrastructures, wider acceptance of multi-analyte panels, advancements in artificial intelligence integrated tools, and greater automation within the testing protocols themselves.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What Are The Main Drivers Boosting The Acute Care Syndromic Testing Industry’s Expansion?

The expanding prevalence of communicable ailments is anticipated to boost the market for acute care syndromic testing moving ahead. These infections, stemming from detrimental microbes like bacteria, viruses, fungi, or parasites that transfer between individuals, creatures, or the surroundings, are becoming more frequent due to elements such as demographic increase, city expansion, international movement, resistance to antimicrobials, and shifts in climate, thus heightening the demand for successful prophylaxis and therapy. Acute care syndromic analysis plays a crucial role in managing these health threats by swiftly pinpointing causal agents and concurrent infections leveraging panels of molecular diagnostic tests, which consequently facilitates prompt, focused therapeutic strategy implementation. As an illustration, data released by the UK’s Health Security Agency in February 2024 revealed that for the fourth week of 2024, the confirmed rate of influenza positivity climbed to 16.6%, a step up from the 14.0% recorded the week immediately preceding it; similarly, consultations related to influenza-like illness (ILI) saw an uptick, registering 9.8 per 100,000 individuals versus the 7.5 per 100,000 reported in the earlier week, while influenza-related hospital admissions also escalated, moving to 7.63 per 100,000 from the previous week’s figure of 5.12 per 100,000. Consequently, the rising tide of infectious diseases serves as a significant impetus for the growth of the acute care syndromic testing sector.

What Are The Key Segments In The Acute Care Syndromic Testing Market?

The acute care syndromic testingmarket covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Which Market Trends Are Creating New Opportunities In The Acute Care Syndromic Testing Industry?

Leading firms within the acute care syndromic testing sector are concentrating efforts on refining existing technologies, notably multiplexed real-time polymerase chain reaction (PCR), with the objectives of boosting diagnostic precision, facilitating swift identification of disease agents, optimizing laboratory operational efficiency, decreasing the time needed to receive results, and ultimately, yielding superior patient results via highly accurate and prompt therapeutic actions.This sophisticated molecular diagnostic approach, known as multiplex real-time PCR, allows for the simultaneous identification and measurement of numerous infectious agents or genetic markers within one PCR run, thereby boosting both the efficiency and exactness of disease identification processes.To illustrate this development, in April of 2023, QIAGEN N.V., a biotechnology firm headquartered in the Netherlands, introduced its QIAstat-Dx syndromic testing platform across Japan, which incorporates a respiratory panel capable of identifying more than twenty distinct pathogens sourced from just one patient specimen, achieving fast outcomes with considerably less effort than employing separate, singular PCR analyses.As of the close of 2022, this system had seen worldwide deployment, exceeding 3,500 installed units, assisting clinicians in diagnosing illnesses affecting the respiratory system, the gastrointestinal tract, and those related to meningitis, with the platform now accessible in more than a hundred nations, significantly broadening the global reach of syndromic testing capabilities.

Which Leading Players Are Enhancing Their Acute Care Syndromic Testing Market Presence Worldwide?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

What Are The Regional Market Dynamics Impacting The Acute Care Syndromic Testing Industry?

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Acute Care Syndromic Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2025, By The Business Research Company

Post Acute Care Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/post-acute-care-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Acute Ischemic Stroke Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Acute Care Syndromic Testing Market Through 2034?

In recent times, the acute care syndromic testing market has seen a significant rise in its size. The market, which is expected to increase from $4.08 billion in 2024 to $4.59 billion in 2025, will be growing at a compound annual growth rate (CAGR) of 12.3%. Factors contributing to the growth in the historic period include enhanced awareness of antimicrobial resistance, increased government funding for infectious diseases, greater investment in healthcare infrastructure, amplified focus on syndromic testing, expansion of telemedicine, and surge in infectious diseases.

Expect an upswing in the size of the acute care syndromic testing market in the coming years, rising to a substantial $7.39 billion in 2029 with a compound annual growth rate (CAGR) of 12.7%. The growth over this forecast period can be traced back to an increase in the occurrence of infectious diseases, a greater need for quick diagnostic solutions, broader healthcare services, the rising adoption of multiplex syndromic panels, and an increasing older population. The forecast period will also see trends like a lean toward point-of-care testing, the incorporation of cloud-based platforms, increased use of multiplex panels, the emergence of AI-powered tools, and the implementation of automation in syndromic testing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

Which Factors and External Forces Are Driving Demand in the Acute Care Syndromic Testing Market?

The increasing occurrences of infectious illnesses is projected to drive the growth of the acute care syndromic testing market. These diseases, caused by harmful microscopic entities like bacteria, viruses, fungi, or parasites can be transmitted from person to person, animals, or even the environment. Aspects such as population growth, urbanization, global travel, antimicrobial resistance, and climate change contribute to these growing occurrences, thereby increasing the necessity for adequate prevention and treatment. The technique of acute care syndromic testing is employed in these infectious diseases to swiftly pinpoint pathogens and co-infections via multiplex molecular diagnostics, facilitating specific treatment decisions. For example, the Health Security Agency, a UK-based government unit, reported in February 2024 that the influenza positivity rate in the fourth week of 2024 surged to 16.6%, a rise from the previous week’s 14.0%. Consultations for influenza-like illnesses (ILI) also increased, hitting 9.8 per 100,000 people, as against 7.5 per 100,000 in the previous week. Likewise, there was an increase in influenza hospitalizations that week, jumping to 7.63 per 100,000 from 5.12 per 100,000 the prior week. Consequently, this escalating prevalence of infectious diseases is bolstering the acute care syndromic testing market.

Which Segments in the Acute Care Syndromic Testing Offer the Most Growth?

The acute care syndromic testingmarket covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Acute Care Syndromic Testing Market?# Market?

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theAcute Care Syndromic Testing Market’s Growth?

Leading firms in the acute care syndromic testing market are placing an emphasis on technological advancements, with particular focus on multiplex real-time polymerase chain reaction (PCR) technology. This is done to boost diagnostic precision, expedite pathogen identification, streamline lab processes, cut down on response time and improve patient results through exact and timely treatment procedures. Multiplex real-time PCR technology is a cutting-edge diagnostic tool that concurrently detects and measures multiple pathogens or genetic targets in a single PCR reaction, thereby improving the efficacy and accuracy of disease diagnosis. In April 2023, for example, a biotechnology research company based in the Netherlands, QIAGEN N.V., unveiled its QIAstat-Dx syndromic testing solution in Japan, which includes a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from one single sample using multiplex real-time PCR technology. This technology allows for faster results with less labor than traditional individual PCR assays. By the close of 2022, over 3,500 systems had been installed worldwide, aiding in the detection of respiratory, gastrointestinal and meningitis-related diseases. With the system available in over 100 countries, syndromic testing has become more accessible globally.

View the full report here:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

What Are the Key Elements That Define the Acute Care Syndromic Testing Market?

Acute care syndromic testing refers to a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. It is used in emergency and critical care settings to quickly diagnose infectious diseases. This enables faster treatment decisions, improved patient outcomes, and reduced hospital stays.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Acute Care Syndromic Testing Market Growth in 2025?

In recent times, the market size of acute care syndromic testing has experienced a fast-paced growth. It is projected to expand from $4.08 billion in 2024 to an estimate of $4.62 billion in 2025 with a compound annual growth rate (CAGR) of 13.2%. Factors such as increased awareness about antimicrobial resistance, a surge in government financing for infectious diseases, greater investment in healthcare infrastructure, a heightened focus on syndromic testing, telemedicine expansion and a rise in infectious diseases are known to have contributed to the growth during the historic period.

What Is the Forecast for the Acute Care Syndromic Testing Market Size Through 2029?

The market size for acute care syndromic testing is anticipated to surge dramatically in the coming years. It is on track to reach a worth of $7.50 billion by 2029, advancing at a compound annual growth rate (CAGR) of 12.9%. The predicted growth in this timeframe can be credited to an increase in infectious disease cases, a surging need for prompt diagnostic solutions, growth in healthcare services, higher utilization of multiplex syndromic panels, and an expanding elderly population. The future trend will see a shift towards point-of-care testing, the incorporation of cloud-based platforms, the usage of multiplex panels, the creation of AI-powered tools, and the automation in syndromic testing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

What are the Key Market Players in Acute Care Syndromic Testing Market and How They’re Evolving?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

What Are the Primary Growth Drivers in the Acute Care Syndromic Testing Market?

The increasing occurrence of infectious diseases is projected to drive the growth of the acute care syndromic testing market. These diseases are caused by harmful microorganisms including bacteria, viruses, fungi, and parasites that can be transmitted among individuals, from animals, or the environment. Factors catalyzing the heightened incidence of infectious diseases include population growth, urbanization, global travel, resistance to antimicrobials, and climate change, thereby amplifying the demand for efficient prevention and treatment methods. Infectious diseases utilize acute care syndromic testing to swiftly detect pathogens and co-infections via multiplex molecular diagnostics, hence enabling targeted treatment options. As an example, the Health Security Agency, a government agency based in the UK, reported that in the fourth week of February 2024, the positivity rate of influenza rose to 16.6%, a growth from 14.0% in the preceding week. Consultations related to Influenza-like illness (ILI) also experienced an increase, escalating to 9.8 per 100,000 people compared to 7.5 per 100,000 in the previous week. Furthermore, admissions to the hospital due to influenza rose to 7.63 per 100,000, from 5.12 per 100,000 the week before. Thus, the escalating occurrence of infectious diseases is fuelling the acute care syndromic testing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

What Are the Leading Segments in the Global Acute Care Syndromic Testing Industry?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

What Are the Key Market Trends in the Acute Care Syndromic Testing Industry?

In the acute care syndromic testing market, key players are driving innovation through developments in technologies such as multiplex real-time PCR, aiming to optimize diagnostic precision, hasten the discovery of pathogens, simplify lab procedures, shorten response time, and uplift patient results via immediate, accurate treatments. Multiplex real-time PCR technology represents a pioneering molecular diagnostic tool that allows for simultaneous detection and measurement of various pathogens or genetic targets within one PCR reaction, thereby accelerating and refining disease diagnosis. For instance, Netherlands-founded biotech research company QIAGEN N.V introduced the QIAstat-Dx syndromic testing solution in Japan in April 2023, designed with a SARS-CoV-2 respiratory panel capable of identifying more than 20 pathogens from a single sample. Utilizing multiplex real-time PCR technology, the system returns swift results with considerably less effort than stand-alone PCR tests. By the close of 2022, over 3,500 units of the system had been implemented worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related diseases. The system is available in more than 100 nations, thus facilitating global access to syndromic testing.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

What Is the Regional Outlook for the Acute Care Syndromic Testing Market?

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

This Report Delivers Insight On:

1. How big is the acute care syndromic testing market, and how is it changing globally?

2. Who are the major companies in the acute care syndromic testing market, and how are they performing?

3. What are the key opportunities and risks in the acute care syndromic testing market right now?

4. Which products or customer segments are growing the most in the acute care syndromic testing market?

5. What factors are helping or slowing down the growth of the acute care syndromic testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Has the Acute Care Syndromic Testing Market Growth Performance Trended Historically, And What Lies Ahead?

In recent years, there has been a significant increase in the size of the acute care syndromic testing market. The market is projected to expand from $4.08 billion in 2024 to $4.62 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.2%. Key factors that have driven growth in this historical period include heightened awareness of antimicrobial resistance, increased government funding for infectious diseases, greater investment in healthcare infrastructure, a heightened emphasis on syndromic testing, the expansion of telemedicine, and the rise in infectious diseases.

The market for acute care syndromic testing is predicted to experience a surge in size in the upcoming years, shooting up to $7.50 billion by 2029 with a compound annual growth rate (CAGR) of 12.9%. Several factors can explain this growth forecast period like the increasing incidence of infectious diseases, the need for quicker diagnostic solutions, expansion in healthcare services, rising usage of multiplex syndromic panels, and an aging population. Significant emerging trends in the forecast period include a move towards point-of-care testing, the incorporation of cloud-based platforms, the adoption of multiplex panels, the creation of AI-driven tools, and the inclusion of automation in syndromic testing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

Which Factors and External Forces Are Driving Demand in the Acute Care Syndromic Testing Market?

The rise in infectious disease cases is anticipated to fuel the expansion of the acute care syndromic testing market. Infectious diseases, which can spread between humans, animals, or from the environment, are health conditions triggered by damaging microorganisms such as bacteria, viruses, fungi, or parasites. The escalating occurrence of these diseases is powered by aspects like population expansion, urbanization, international travel, antimicrobial resistance, and changes in climate, thereby augmenting the necessity for efficient prevention and treatment methods. Acute care syndromic testing plays a crucial role in quickly detecting pathogens and co-infections in infectious diseases by utilizing multiplex molecular diagnostics, paving the way for precision-based treatment decisions. For instance, the Health Security Agency reported in Week 4 of February 2024 that the influenza positivity rate had escalated to 16.6%, a rise from the earlier week’s 14.0%. The influenza-like illness (ILI) consultations also surged to 9.8 per 100,000 individuals from the previous week’s 7.5 per 100,000. Furthermore, influenza hospitalizations also saw a significant increase, reaching 7.63 per 100,000 from the preceding week’s 5.12 per 100,000. Consequently, the increasing prevalence of infectious diseases is steering the growth of the acute care syndromic testing market.

Which Segments in the Acute Care Syndromic Testing Offer the Most Growth?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Acute Care Syndromic Testing Market?# Market?

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theAcute Care Syndromic Testing Market’s Growth?

Top-tier companies working in the acute care syndromic testing market are honing their focus on technological advancements like multiplex real-time polymerase chain reaction (PCR) technology. Their aim is to boost diagnostic accuracy, facilitate quick detection of pathogens, structure lab workflows efficiently, reduce waiting period, and enhance patient results through accurate and on-time treatment strategies. The multiplex real-time PCR technology, an advanced molecular diagnostic approach, can simultaneously detect and measure multiple pathogens or genetic targets within a single PCR reaction thus escalating efficiency and correctness in disease diagnosis. For example, in April 2023, QIAGEN N.V., a biotech research firm based in the Netherlands, introduced the QIAstat-Dx syndromic testing solution in Japan. It includes a SARS-CoV-2 respiratory panel capable of detecting more than 20 pathogens from one single sample. This technology, which uses multiplex real-time PCR, can produce quick results with less labor as compared to individual PCR tests. By the culmination of 2022, there were globally more than 3,500 systems installed that aid in diagnosing conditions relating to the respiratory system, gastrointestinal tract, and meningitis. Available in over 100 nations, it is effectively promoting syndromic testing accessibility worldwide.

View the full report here:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

What Are the Key Elements That Define the Acute Care Syndromic Testing Market?

Acute care syndromic testing refers to a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. It is used in emergency and critical care settings to quickly diagnose infectious diseases. This enables faster treatment decisions, improved patient outcomes, and reduced hospital stays.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theAcute Care Syndromic Testing Market?

The increasing occurrence of infectious diseases is anticipated to propel the acute care syndromic testing market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread between individuals, animals, or the environment. The rising number of infectious diseases is influenced by population growth, urbanization, global travel, antimicrobial resistance, and climate change, intensifying the need for effective disease prevention and treatment. Acute care syndromic testing facilitates rapid identification of pathogens and co-infections using multiplex molecular diagnostics, enabling targeted treatment approaches. For instance, in February 2024, the Health Security Agency, a UK-based government organization, reported that in week 4 of 2024, the influenza positivity rate increased to 16.6%, up from 14.0% the previous week. Influenza-like illness (ILI) consultations also climbed to 9.8 per 100,000 people, compared to 7.5 per 100,000 the prior week. Additionally, influenza-related hospitalizations rose to 7.63 per 100,000, up from 5.12 per 100,000 the previous week. Therefore, the increasing prevalence of infectious diseases is fueling the growth of the acute care syndromic testing market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp

#How Does the ProjectedAcute Care Syndromic Testing Market Growth Compare Over the Forecast Period?

The acute care syndromic testing market has expanded rapidly in recent years. It is forecasted to rise from $4.08 billion in 2024 to $4.62 billion in 2025, with a CAGR of 13.2%. The past growth was driven by heightened awareness of antimicrobial resistance, increased government funding for infectious diseases, greater investment in healthcare infrastructure, a growing emphasis on syndromic testing, the expansion of telemedicine, and the rising prevalence of infectious diseases.

The acute care syndromic testing market size is expected to grow rapidly in the coming years. By 2029, it is estimated to reach $7.50 billion at a compound annual growth rate (CAGR) of 12.9%. This growth is driven by the increasing prevalence of infectious diseases, rising demand for faster diagnostic solutions, the expansion of healthcare services, greater use of multiplex syndromic panels, and an aging global population. Key trends forecasted for this period include a shift towards point-of-care testing, integration of cloud-based platforms, adoption of multiplex panels, the development of AI-powered diagnostic tools, and increased automation in syndromic testing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078

Which Cutting-Edge Market Trends Are Expected to Drive theAcute Care Syndromic Testing Market’s Growth?

In the acute care syndromic testing market, companies are advancing multiplex real-time PCR technology to enhance diagnostic accuracy and enable rapid pathogen detection. For instance, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in April 2023. This system, capable of detecting over 20 pathogens from a single sample, provides rapid results with minimal labor, significantly improving diagnostic efficiency and patient outcomes.

What Are the Leading Market Players Impacting theAcute Care Syndromic Testing Market’s Growth Trend?

Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report

How Are the Key Segments of the Acute Care Syndromic Testing Market Driving Opportunities and Innovations?

The acute care syndromic testing market covered in this report is segmented –

1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types

2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types

3) By Target: Bacteria, Viruses, Fungi, Parasites

4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments:

1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases

2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases

3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases

4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases

5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theAcute Care Syndromic Testing Market?# Market Expansion?

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2025, By The Business Research Company:

Anthrax Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Dendritic Cell Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: